By Chelsea Naso ( November 13, 2018, 3:32 PM EST) -- AstraZeneca will sell the U.S. rights to a respiratory drug to Sobi for $1.5 billion in cash and stock up front as part of a push to streamline its portfolio of drugs, the U.K.-based pharmaceutical giant said Tuesday....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.